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Case reportHepatic failure, neonatal hemochromatosis and 
porto-pulmonary hypertension in a newborn with 
trisomy 21 - a case report
Erin Neil1, Josef Cortez1,2, Aparna Joshi3, Erawati V Bawle1,4, Janet Poulik5, Mark Zilberman1,6, Mohammad F El-Baba1,7 
and Beena G Sood*1,2
Abstract
Liver failure in neonates is a rare but often fatal disease. Trisomy 21 is not usually associated with significant infantile 
liver disease. If present, hepatic dysfunction in an infant with Trisomy 21 is likely to be attributed to transient 
myeloproliferative disorder with hepatic infiltration by hematopoietic elements and may be associated with secondary 
hemosiderosis. A less commonly recognized cause of liver failure in neonates with Trisomy 21 is neonatal 
hemochromatosis (NH); this association has been reported in nine cases of Trisomy 21 in literature. NH is a rare, severe 
liver disease of intra-uterine onset that is characterized by neonatal liver failure and hepatic and extrahepatic iron 
accumulation that spares the reticuloendothelial system. NH is the most frequently recognized cause of liver failure in 
neonates and the commonest indication for neonatal liver transplantation. Although porto-pulmonary hypertension 
(PPH) has been reported as a complication of liver failure in adults and older children, this has not been reported in 
neonates with liver failure of any etiology. This is probably due to the rarity of liver failure in newborns, delayed 
diagnosis and high mortality. The importance of recognizing PPH is that it is reversible with liver transplantation but at 
the same time increases the risk of post-operative mortality. Therefore, early diagnosis of PPH is critical so that early 
intervention can improve the chances of successful liver transplantation. We report for the first time the association of 
liver failure with porto-pulmonary hypertension secondary to NH in an infant with Trisomy 21.
Background
Neonatal hemochromatosis (NH) is the most frequently
recognized cause of liver failure in neonates and the com-
monest indication for neonatal liver transplantation.
Porto-pulmonary hypertension, a serious complication of
liver failure in adults and children, has not previously
been described in neonates. Trisomy 21 is not usually
associated with significant infantile liver disease [1].
Hepatic dysfunction in an infant with Trisomy 21 is likely
to be attributed to transient myeloproliferative disorder
(TMD) with hepatic infiltration by hematopoietic ele-
ments and may be associated with secondary hemosi-
derosis [2]. A less commonly recognized cause of liver
failure in neonates with Trisomy 21 is NH; this associa-
tion has been reported in nine cases of Trisomy 21 in lit-
erature [3]. We report for the first time the association of
porto-pulmonary hypertension with liver failure second-
ary to NH in an infant with Trisomy 21.
Case Presentation
BGB was delivered at 37 weeks (birth weight 3550 g) ges-
tation by a 37 year old Caucasian woman with a past his-
tory of one term delivery, one ectopic pregnancy and one
miscarriage. She declined prenatal serum triple screen
testing. Cesarean section was performed for non-reactive
non-stress test. Apgar scores were 7 and 8 at one and five
minutes respectively. The infant was noted to have a vig-
orous cry, cyanosis, generalized edema, diffuse ecchy-
moses and petechiae, and physical features suggestive of
Down syndrome; the latter diagnosis was subsequently
confirmed on chromosomal analysis which showed Tri-
somy 21. Oxygen saturation in room air was 59% and
improved with supplemental oxygen by hood. Initial
white cell count was 20,700/cmm, hematocrit 38% and
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platelet count 37,000/cmm. A chest radiograph revealed
cardiomegaly. At one hour of age the infant was noted to
have a loud holosystolic murmur over the precordium.
Early persistent hypoglycemia despite treatment was doc-
umented. The infant was transferred to a level III NICU
for evaluation for a heart defect and non-immune
hydrops in an infant with probable trisomy 21. The pla-
cental pathology was later reported as hydropic placenta
with villous dysmaturity, pigment laden macrophages,
and microcalcifications with no evidence of villitis or leu-
kemic infiltrates.
At the referral hospital, an echocardiogram showed
normal anatomy with evidence of pulmonary hyperten-
sion. Direct hyperbilirubinemia was observed on the first
day of life (D1) (total bilirubin 10.4, direct bilirubin 3.6
mg/dl). Coagulation studies were abnormal. TMD was
suspected; however, flow cytometry, peripheral smear
and immunophenotyping were not supportive of the
diagnosis. Abdominal ultrasound showed ascites, normal
appearing liver, spleen and kidneys, and absence of portal
hypertension. On D2, the infant developed hypotension
that was treated with escalating doses of dopamine, dob-
utamine, and epinephrine drips and hydrocortisone. Her
liver function progressively deteriorated, evident by
worsening coagulation profile, increasing direct hyperbil-
irubinemia, hypoalbuminemia, hypoglycemia, and wors-
ening edema. Laboratory test results included: normal
serum transaminases, ammonia and lactate; serum albu-
min 1.1 g/dl; AFP 459.3 ng/ml; serum Fe 123 z-mcg/dl;
TIBC 160 z-mcg/dl; Ferritin 525 ng/ml; Factor V activity
11%; Factor VII activity 3.2%; factor VIII activity 95%.
Microbiologic and serologic work up ruled out TORCH,
parvovirus, adenovirus and enterovirus infections. Urine
reducing substances, quantitative plasma amino acids,
and tests for organic acidemias, fatty oxidation defects
and inborn errors of bile acid synthesis were normal. She
was supported with blood, plasma, and albumin transfu-
sions. On D3, she was placed on assisted ventilation for
persistent hypoxemia. Inhaled nitric oxide was initiated
on D7 for persistent pulmonary hypertension on
echocardiogram (bidirectional shunting across foramen
ovale and ductus arteriousus, tricuspid valve insuffi-
ciency, dilated right ventricle with markedly elevated
right ventricular systolic pressure of 74 mm Hg; Figure 1)
with only marginal improvement in oxygenation. A diag-
nosis of hepatic failure secondary to NH associated with
porto-pulmonary hypertension was entertained. Mag-
netic resonance imaging of the abdomen was suggestive
of NH (Figure 2). A lip biopsy on D8 confirmed hemosid-
erin deposition in salivary glandular epithelium (Figure
3a).
Treatment with double volume exchange transfusion
followed by administration of immunoglobulin (IVIG)
and an antioxidant cocktail of selenium, prostaglandin E1,
N-acetyl-cyteine, desferoxamine, and vitamin E was initi-
ated on D7. However, her cardiorespiratory status contin-
ued to deteriorate and she expired on the 10th day of life.
Permission for autopsy was obtained.
Microscopically, the liver showed diffuse fibrosis,
ductular and pseudoductular proliferation, fibrous oblit-
eration of central veins, and hepatocellular and cholangi-
olar cholestasis. Foci of extramedullary hematopoiesis
were identified. No leukemic infiltrates were identified.
Hepatocellular and ductular deposition of iron was con-
firmed (Figure 3b). The pancreas showed diffuse fibrosis
without megakaryocytes or leukemic infiltrates. Moder-
ate iron deposition was demonstrated in the pancreas and
myocardium but not in the spleen (Figure 3c-d). Micro-
scopic examination of the lungs revealed interstitial fibro-
sis, focal type II pneumocyte hyperplasia, and few
peripheral arterioles with thick walls. The radial alveolar
count was less than three in many areas (expected 4-5).
Discussion
Liver failure in neonates is a rare but often fatal event.
Causes include inborn errors of metabolism, perinatal
infections, hypotension/shock, and hematological condi-
tions like TMD, congenital leukemia and hemophago-
cytic lymphohistiocytosis [4,5]. Whereas metabolic liver
diseases typically present weeks to months after birth and
infectious diseases weeks after birth, neonatal NH pres-
ents soon after birth. In NH, the onset of the liver disease
is in utero, with end-stage liver disease already estab-
lished even in the prematurely born infant [6,7]. It is the
most frequently recognized cause of liver failure in neo-
nates and the commonest indication for neonatal liver
transplantation.
In NH, severe fetal liver injury often leads to fetal loss
as evidenced by the obstetric histories of women who
Figure 1 Color M-mode of ductal flow on echocardiography. In 
systole (as indicated by the ECG marker) the flow is blue, i.e. from the 
pulmonary artery into the aorta; in diastole (as indicated by the ECG 
marker) the flow is red, i.e. from the aorta into the pulmonary artery.
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have had an infant diagnosed with NH [7,8]. Intrauterine
growth restriction, oligohydramnios or polyhydramnios,
fetal distress and placental edema may be present. Infants
who are not stillborn exhibit liver and multiorgan failure
within the first few days of life. Jaundice with significant
elevations of both conjugated and nonconjugated biliru-
bin, hypoglycemia, marked coagulopathy, thrombocy-
topenia, anemia, hypoalbuminemia, edema, ascites, and
oliguria are prominent features [6]. Typical biochemical
findings include an extremely high serum ferritin level
(usually > 800 ng/mL), and extremely high levels of AFP
(usually > 200 ng/mL). An unusual characteristic given
the degree of liver injury is low or absent serum transam-
inases. Hepatocellular synthetic insufficiency leads to
hypoglycemia, coagulopathy (factors V and VII usually
less than 10% of normal, low fibrinogen), hypoalbumine-
mia (usually less than 2 gm/dL) and decreased iron-bind-
ing capacity. Liver histology is characterized by intense
fibrosis and cirrhosis without acute necrosis. However,
none of these findings is diagnostic of NH.
The diagnosis of NH is based on the clinical features of
liver failure at birth with extrahepatic siderosis and spar-
ing of the reticuloendothelial system in the absence of
other causes of liver failure. Extrahepatic siderosis can be
demonstrated non-invasively in these critically ill infants
on magnetic resonance imaging (MRl) and lip biopsy
[6,9-11]. Hepatic siderosis is not specific for NH, rather it
is observed in the normal infant liver and more promi-
nently in a multitude of liver diseases. Therefore liver
biopsy, a hazardous procedure in the presence of coagul-
opathy, is not diagnostic for NH.
The prognosis for patients with NH is grim; most suc-
cumb to the complications of end-stage liver disease
within the first few weeks of life if not successfully res-
cued by liver transplantation [7,12-16]. Treatment with
either anti-oxidant/chelator cocktail, or exchange trans-
fusion and IVIG has been reported to be successful in
small series of patients but these therapies have not been
systematically evaluated. The survival after liver trans-
plantation is 50% (median follow up 7.8 years, range 3-10
years). There is a high recurrence rate (~80%) of NH in
families following the birth of an affected child.
The case presented here had several typical features of
NH. The unique features of the infant presented in this
Figure 2 a and b: T1-weighted (1A) and T2-weighted (1B) spin echo axial MR images at the level of the heart show marked drop in myocar-
dial signal intensity (arrow) on T2-weighted image, reflecting myocardial hemosiderin deposition. c and d: Axial T2 STAR gradient echo MR 
images of the abdomen at the level of the liver and spleen (Fig. 2) and liver and pancreas (Fig. 3) show low signal intensity in the liver (L) and pancreas 
(P) and normal signal intensity in the spleen (S), reflecting hepatic and pancreatic siderosis.
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report are the association of NH with Trisomy 21 (tenth
reported case in literature) and the association of NH
with PPH. Although PPH has been reported with end-
stage liver disease (ESLD) in adults and older children,
this is the first report of PPH in association with liver fail-
ure secondary to NH, an end-stage liver disease seen in
the neonatal period [17]. The diagnosis of PPH in adults
and older children requires the presence of pulmonary
hypertension in the setting of liver disease or portal
hypertension. It has been proposed that binding of
endothelin-A receptors by increased circulating levels of
endothelin 1 (ET-1) produced by the cirrhotic liver lead
to vasoconstriction and vascular smooth muscle prolifer-
ation which manifests as PPH. Although the diagnosis of
PPH is made on the basis of hemodynamic criteria, pres-
ence of morphologic features of pulmonary hypertension
has been described in a few case series of pediatric ESLD
[18,19]. Because of the rarity of PPH, diagnosis is often
delayed. Clinical diagnosis requires a high degree of sus-
picion and deliberate follow-up by echocardiography for
the timely detection of pulmonary hypertension before
irreversible vascular damage occurs. In our patient, pul-
monary hypertension that was present since the first day
of life worsened progressively inspite of treatment.
Infants with Trisomy 21 have an increased risk for devel-
oping persistent pulmonary hypertension in the neonatal
period as well as primary pulmonary hypertension later
in life even in the absence of structural heart disease
[20,21]. The predisposition to neonatal pulmonary hyper-
tension has been attributed to a combination of reduced
alveolar count (as was observed on autopsy in our
patient), reduced capillary surface area and an abnormal
pulmonary vasculature. Pulmonary hypertension in neo-
nates with Trisomy 21 typically responds to medical ther-
apy. Several features suggest that the pulmonary
hypertension observed in this neonate was attributable to
ESLD, with the presence of Trisomy 21 being a contribu-
tory factor - the fact that the hypoxemia responded to
supplemental oxygen in the first two days and then wors-
ened progressively with worsening liver failure despite
treatment with assisted ventilation and inhaled nitric
oxide. The neonate with ESLD differs from adults and
children with ESLD in that pulmonary hypertension is
normal during fetal life because the placenta, not the
lung, serves as the organ of gas exchange and the pres-
ence of ESLD may prevent the normal postnatal drop in
pulmonary vascular resistance soon after birth. Therefore
hemodynamic criteria for porto-pulmonary hypertension
Figure 3 Prussian blue stain showing iron deposition (original magnification × 200). a - Salivary gland with iron deposition in glandular epithe-
lium. b - Liver with diffuse fibrosis, ductular proliferation, fibrous obliteration of central veins and hepatocellular and ductular iron deposition. c - Pan-
creas with interstitial fibrosis and deposition of iron in acinar epithelial cells. d - Myocardium with perinuclear iron deposition.
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may be present in the absence of morphologic criteria
because of presentation of liver failure soon after birth.
The importance of recognizing PPH is that it is reversible
with liver transplantation but at the same time increases
the risk of post-operative mortality. It has been suggested
that screening with echocardiography be considered for
all adults and children with ESLD for early diagnosis of
PPH. We suggest that this recommendation be also
applied to newborns with fulminant liver failure to
improve outcomes.
Conclusions
This case emphasizes the importance of recognition of
NH as a cause of liver failure in infants with Trisomy 21
and the association porto-pulmonary hypertension with
neonatal liver failure. The finding of coagulopathy and
hyperbilirubinemia in an infant with hypoalbuminemia,
ascites, or splenomegaly should prompt the consideration
of neonatal liver failure. Although NH is a rare disease, it
is the commonest cause of neonatal liver failure and
should be part of the differential diagnoses of any neonate
presenting with liver failure. Lip biopsy and MRI to dem-
onstrate extrahepatic siderosis are important in confirm-
ing the diagnosis after excluding other causes. These
infants should be screened for PPH by echocardiography
as this influences outcome. Early recognition of NH can
improve survival by early referral for liver transplanta-
tion. Diagnosis of NH also has implications for recur-
rence in future pregnancies.
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